Roquefort Therapeutics plc
ROQ.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £2 | £5 | £6 | £10 |
| - Cash | £0 | £0 | £1 | £1 |
| + Debt | £0 | £0 | £1 | £0 |
| Enterprise Value | £2 | £5 | £6 | £9 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | -100% | – | – |
| Gross Profit | £0 | -£0 | -£0 | -£0 |
| % Margin | – | – | -592.2% | – |
| EBITDA | -£0 | -£0 | -£1 | -£1 |
| % Margin | – | – | -24,999.6% | – |
| Net Income | -£0 | -£0 | -£1 | -£1 |
| % Margin | – | – | -21,447.1% | – |
| EPS Diluted | -0.003 | -0.003 | -0.005 | -0.007 |
| % Growth | -10% | 33.3% | 36.6% | – |
| Operating Cash Flow | -£0 | -£0 | -£1 | -£1 |
| Capital Expenditures | -£0 | £0 | -£0 | £0 |
| Free Cash Flow | -£0 | -£0 | -£1 | -£1 |